- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05563350
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
Association Between Variations in CYP Pheno- and Genotypes and Plasma Concentration of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pharmacological treatment caries a risk of overdosing and adverse events. Chlordiazepoxide, among other sedative drugs, has been associated with an increased risk of death. Chlordiazepoxide treatment for alcohol withdrawal symptoms will render some patients in need of ventilatory support and ICU admission. Other patients will not obtain the desired effect from the treatment and will be in a state of agitation despite having received high doses of chlordiazepoxide. This individual variation in effect is not predictable and may be explained by variations in the capacity of drug metabolism.
Chlordiazepoxide is extensively metabolized in the liver by hepatic microsomal enzymes and exhibits capacity limited, protein binding sensitive, hepatic clearance. Metabolism is primarily by cytochrome P450 (CYP), especially CYP3A4 and CYP2C19 systems. Evaluation of CYP phenotypes by drug probe phenotyping is extensively used. Midazolam possesses several characteristics that makes it useable as a pharmacological probe for CYP3A activity despite having already received other benzodiazepines. It is metabolized to a primary metabolite exclusively by CYP3A4/3A5.Omeprazole can likewise be used as a pharmacological probe for CYP2C19.
The drug of investigation is chlordiazepoxide, which has been given before study inclusion. After inclusion and during the study period (12 hours), it is not allowed to administer chlordiazepoxide to the patient. In case of abstinence, the recommended therapy is diazepam or propofol.
Blood samples will be collected and plasma concentrations of chlordiazepoxide and metabolites will be analyzed and compared with the amount of chlordiazepoxide administered at inclusion and 12 hours after inclusion.
Independent variables:
- Variations in genotypes of CYP3A4/3A5 and CYP2C19.
- Phenotypes of CYP3A4/3A5 and CYP2C19, analyzed as above /below the median value of enzyme activity.
Variations in genotypes of CYP3A4/3A5 and CYP2C19 will be analyzed from blood samples.
Phenotyping of CYP3A4/3A5 and CYP2C19 will be performed with midazolam and omeprazole as pharmacological probes respectively. 2 mg of midazolam and 10 mg of omeprazole will be administered intravenously as bolus within 12 hours after inclusion. Blood samples 2 h after dosing (t=2 h dosing) will be collected and analyzed for plasma concentrations of omeprazole, hydroxyomeprazole, midazolam and 1-hydroxymidazolam. The ratio between omeprazole and hydroxyomeprazole will be used to classify the CYP2C19 phenotype as the ratio between midazolam and 1-hydroxymidazolam will be used in the classification of CYP3A4/3A5
By measuring concentration of chlordiazepoxide and the ability to metabolize chlordiazepoxide in ICU- or HDU-patients with respiratory insufficiency, impaired consciousness or agitation after treatment for alcohol withdrawal symptoms, we will investigate if there is a correlation between the patient's phenotypes of the CYP3A4/3A5 and CYP2C19 systems (independent variable) and the concentration of chlordiazepoxide (primary outcome).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2400
- Bispebjerg and Frederiksberg Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years
- Treatment with minimum 200 mg chlordiazepoxide for alcohol withdrawal symptoms during hospital admission
- Acute admittance to ICU or HDU due to respiratory insufficiency, impaired consciousness or agitation.
- Inclusion possible within 12 h of ICU/HDU admission.
Exclusion Criteria:
- Allergies to omeprazole/esomeprazole and midazolam
- Treatment with chlordiazepoxide within the first 12 h after inclusion (from blood samples at inclusion until blood samples 12 h after inclusion)
- Treatment with omeprazole/esomeprazole within 1 day prior to ICU/HDU admission and within the first 12 h after inclusion.
- Treatment with midazolam within 1 day prior to ICU/HDU admission
- Cardiac arrest prior to admission
- Pregnancy (a negative hcg (from urine or blood sample) has to be present before inclusion of women aged <50 years)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration of chlordiazepoxide and metabolites
Time Frame: At inclusion and 12 hours after inclusion
|
p-chlordiazepoxide and metabolites.
|
At inclusion and 12 hours after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Half-life (T½) for chlordiazepoxide
Time Frame: At inclusion and 12 hours after inclusion
|
Half-life (T½) for chlordiazepoxide will be estimated from the area under the concentration time curve (AUC) from concentrations of chlordiazepoxide at inclusion and 12 hours after inclusion.
|
At inclusion and 12 hours after inclusion
|
Cumulative dose of chlordiazepoxide before admission to ICU/HDU
Time Frame: From date of hospital admittance until the date of inclusion in the study no later than 12 hours after admission on either ICU or HDU
|
Chlordiazepoxide dose in mg
|
From date of hospital admittance until the date of inclusion in the study no later than 12 hours after admission on either ICU or HDU
|
ICU/HDU and hospital length of stay (LOS) within 90 days
Time Frame: 90 days after ICU admission and 90 days after hospital admission
|
ICU Length of stay and Hospital length of stay
|
90 days after ICU admission and 90 days after hospital admission
|
Need for mechanical ventilation within 90 days
Time Frame: 90 days after inclusion
|
Duration of treatment with mechanical ventilation
|
90 days after inclusion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nanna Reiter, MD, Bispebjerg and Frederiksberg Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Substance Withdrawal Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Midazolam
- Omeprazole
Other Study ID Numbers
- KLOPOXID2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Withdrawal
-
VA Salt Lake City Health Care SystemCompleted
-
Denver Health and Hospital AuthorityTerminatedAlcohol Withdrawal Delirium | Alcohol Withdrawal Associated Autonomic Hyperactivity | Alcohol Withdrawal Hallucinosis | Alcohol Withdrawal-Induced Delirium TremensUnited States
-
University of Colorado, DenverWithdrawnAlcohol WithdrawalUnited States
-
Stanford UniversityCompletedAlcohol WithdrawalUnited States
-
Unity Health TorontoTerminatedAlcohol Withdrawal | Alcohol Withdrawal Delirium | Alcohol Withdrawal SeizuresCanada
-
Medical University of ViennaCompletedPsychophysiologic Reaction | Alcohol WithdrawalAustria
-
Jubilee Mission Medical College and Research InstituteINCRE fellowship from DBT, govt of IndiaCompletedAlcohol Withdrawal Symptoms | Delirium Tremens (DTs)
-
University Hospital, MontpellierCompletedAddiction | Alcohol Use Disorder | Alcohol Withdrawal SyndromeFrance
-
Yale UniversityRecruiting
-
Jonathan RosensonAlameda County Medical CenterCompleted
Clinical Trials on Blood samples
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Georges Francois LeclercCompleted
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Institut BergoniéUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedHenoch Schönlein PurpuraFrance
-
Assistance Publique Hopitaux De MarseilleRecruitingPlastic SurgeriesFrance
-
University Hospital, BordeauxRecruitingSystemic Sclerosis | SclerodermaFrance
-
Centre Hospitalier Universitaire, AmiensCompleted